spironolactoneqtprolongation

由 SP Etheridge 著作 · 2003 · 被引用 204 次 — Therapy with KCl and spironolactone resulted in a sustained, mild increase in serum K+from 4.0 ± 0.3 to 5.2 ± 0.3 mEq/l, with no adverse events. The increase in ...

由 S Snitker 著作 · 2017 · 被引用 31 次 — Spironolactone was associated with a mean QTc shortening of −3 milliseconds, except when adjusted for serum potassium and calcium. The ...

由 S Snitker 著作 · 2017 · 被引用 31 次 — Most of the QT prolongation associated with metolazone and furosemide, but not spironolactone, remained after adjustment for potassium and calcium. Proton pump ...

Prolongation of the QT interval can lead to a life threatening ventricular arrhythmia known as torsades de pointes which can result in sudden cardiac death.

由 LM Angus 著作 · 2024 — The QT interval appears to be modulated by serum testosterone concentrations; it is prolonged in men treated with androgen deprivation therapy ...

由 P Marstrand 著作 · 2021 · 被引用 5 次 — We demonstrate that 100 mg spironolactone and potassium supplements increased plasma potassium by 0.4 mmol/L without any cases of hyperkalaemia. However, this ...

由 M Akbulut 著作 · 2003 · 被引用 33 次 — The addition of spironolactone or metoprolol to a standard conventional heart failure treatment significantly decreases the QTd or QTdc intervals, which are ...

由 J Klimas 著作 · 2015 · 被引用 36 次 — Aldosterone antagonists, eplerenone in animals and spironolactone in humans, have been found to modulate the duration of the QT interval.

由 R Caballero 著作 · 2003 · 被引用 85 次 — Background— It has been demonstrated that spironolactone (SP) decreases the QT dispersion in chronic heart failure.